详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

单位： [1]Fudan Univ, Liver Canc Inst, Shanghai, Peoples R China [2]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [3]Shanghai Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg, Shanghai, Peoples R China [4]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China [5]USTC, Anhui Prov Hosp, Affiliated Hosp 1, Dept Hepatobiliary Surg, Hefei, Peoples R China [6]Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China [7]Tianjin Med Univ Canc Inst & Hosp, Liver Canc Ctr, Tianjin, Peoples R China [8]Sun Yat Sen Univ, Dept Hepatobiliary Oncol, Ctr Canc, Guangzhou, Peoples R China [9]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou, Peoples R China [10]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China [11]Peoples Hosp Zhengzhou, Dept Hepatobiliary Pancreat Surg, Zhengzhou, Peoples R China [12]SCU Sichuan Univ, Dept Liver Surg, Huaxi Campus, Chengdu, Peoples R China [13]Peking Univ, Peoples Hosp, Dept Liver Surg, Beijing, Peoples R China [14]Fujian Med Univ Canc Hosp, Mengchao Hepatobiliary Hosp, Dept Hepatobiliary Surg, Fuzhou, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 56.7 最新[2023版] 38.2 最新五年平均 32.976 出版当年[2020版] 22.846 出版当年五年平均 18.274 出版前一年[2019版] 51.769 出版后一年[2021版]

第一作者：

第一作者单位： [1]Fudan Univ, Liver Canc Inst, Shanghai, Peoples R China [2]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：